Coronavirus: Chinese company signs deal to get access to appealing Oxford University vaccine

Five out of the six vaccines that are presently undergoing phase 3 human trials will be readily available in China. Photo: AFP

Shenzhen Kangtai Biological Products signs accrediting deal with AstraZeneca and hopes to produce 200 million dosages a year
Vaccine produced encouraging test leads to stage 2 trials by triggering an immune action amongst volunteers

Topic |.
Coronavirus pandemic

Released: 9: 00 pm, 7 Aug, 2020

Upgraded: 8: 53 pm, 8 Aug, 2020